Teprotumumab and hearing loss: hear the warnings.

Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel. In Smith et al.[2] hearing impairment was reported in 3 of 43 patients (7%) who received teprotumumab: one experienced unilateral hearing loss (16 weeks after the end of therapy), one had bilateral hearing loss (resolved), and one developed tinnitus (in the setting of previous history of tinnitus; resolved). [Extracted from the article]